Understanding how Bispecific T cell engagers work: remarkable mode of action! Let’s hope it works as well as in oncology! #teclistamab in #SSc #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/waSCXKA79Y

#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw

#CAR_T cell therapy in #SSc Promising results from the Breakfree-1 study (Zola-cel) on safety and preliminary efficacy on pFVC in 26 patients More data is needed #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/ZS1LnBLMu5

Looking forward to CAR T cell therapy trials in #SSc Phase 2 and 3 studies presented at #HOT session by Pr Oliver Distler #CAR_T #EULAR2026 @RheumNow https://t.co/bmXZpF2wKg

#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H

Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8

Many drugs in the pipeline for #Systemic_Sclerosis In particular, stay tuned for: 🔺Nerandomilast (PDE4i) in ILD 🔺CAR T cells (obviously): big RCT trials planned 🔺Bispecific T cell engagers: Teclistamab #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/I7HQtfwuW0

103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up. Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64

How many patients from real life fulfill the inclusion criteria of clinical trials? Not so many ⬇️ #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/U6vlzOYS4X